NOTE: This video is ONLY available to watch in selected countries and geographies [geoip-content country=”AT, BE, BG, HR, CY, CZ, DK, EE, FI, DE, GR, HU, IE, IT, LV, LT, LU, MT, NL, PL, PT, RO, SK, SI, CH, ES, SE, GB, AL, AD, AM, AZ, BY, BA, GE, IS, KZ, LI, MD, MC, ME, MK, NO, RU, SM, RS, CH, TR, UA, VA”]
Gunnar Tepe (interventional radiologist, Germany) discusses the results and subsequent impact of the EMINENT randomised controlled trial on his practice, explaining that the Eluvia stent has a “significantly better” patency rate when compared to conventional stents.
This video was filmed by Boston Scientific and is being sponsored for distribution in association with Vascular News. Biba Medical bears no responsibility for the assets used in the production of this video.
View the clinical trial results
Evidence in the SFA: Best strategy for treatment of the femoropopliteal segment
Evidence in the SFA: What kind of stent should we use?
Evidence in the SFA: Considering the data when making decisions for patients
Evidence in the SFA: DES ‘will be the standard of care’ when treating SFA femoropopliteal lesions
[/geoip-content]
